VANCOUVER, BC – Clairvoyant Therapeutics (“Clairvoyant”), a Canadian biotech company focused on the development of psychedelic drug therapies for addiction, is pleased to announce Greg Engel has joined the company’s Board of Directors and Long… Read More
BURNABY, BC – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and… Read More
OTTAWA, ON — Canadians look to the 44th Parliament to apply lessons learned from COVID-19 to protect current and future generations. This includes building healthcare systems equipped for both exceptional… Read More
BURNABY, BC – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares… Read More
MISSISSAUGA, ONT – GSK today announced it has signed an agreement with the Government of Canada to supply 10,000 doses of Sotrovimab for injection, a COVID-19 monoclonal antibody therapy developed… Read More
